Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01502072 · ClinicalTrials.gov registry record · Phase 2
Respiratory Syncytial Virus - RSV Protocol
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT01502072: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01502072 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 48 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01502072, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if ribavirin can help to control RSV in patients with immune systems that have been weakened by a stem cell transplant. Researchers also want to compare the effectiveness of the drug when it is given by mouth to when it is inhaled. The safety of the drug in both methods of delivery will be studied. Ribavirin is designed to prevent the RSV virus from making more copies of itself in the body.
Interventions
- DRUG Ribavirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2011-12-28 |
| Est. Completion | 2020-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01502072
The ClinicalTrials.gov registry entry for NCT01502072 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ribavirin is the first listed.
NCT01502072 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01502072 about?
NCT01502072 is a clinical study titled "Respiratory Syncytial Virus - RSV Protocol". The goal of this clinical research study is to learn if ribavirin can help to control RSV in patients with immune systems that have been weakened by a stem cell transplant. Researchers also want to compare the effectiveness of the drug when it is given by mouth to when it is inhaled. The safety of t...
What is the current status of trial NCT01502072?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2011-12-28. Estimated completion is 2020-02-01.
What interventions are being tested in trial NCT01502072?
The interventions under investigation include: Ribavirin (DRUG).
Who is sponsoring clinical trial NCT01502072?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.